Agilent Technologies (NYSE:A) should head towards $49.38 per share according to 8 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $45 per share. The higher price estimate target is at $55 according to the Analysts.
Many analysts have stated their opinion on the company shares. Major Brokerage house, Cowen & Company maintains its ratings on Agilent Technologies (NYSE:A). In the latest research report, Cowen & Company raises the target price from $47 per share to $49 per share. According to the latest information available, the shares are now rated Outperform by the analysts at the agency. The rating by the firm was issued on May 26, 2016. For the current week, the company shares have a recommendation consensus of Buy.
On the companys insider trading activities, The director, of Agilent Technologies Inc, Cullen James had unloaded 16,697 shares at $45.78 per share in a transaction on May 27, 2016. The total value of transaction was $764,389. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Agilent Technologies (NYSE:A) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.44 points or 0.97% at $44.92 with 1,272,833 shares getting traded. Post opening the session at $45.32, the shares hit an intraday low of $44.905 and an intraday high of $45.52 and the price was in this range throughout the day. The company has a market cap of $14,622 million and the number of outstanding shares have been calculated to be 325,521,700 shares. The 52-week high of Agilent Technologies (NYSE:A) is $46.18 and the 52-week low is $33.115.
Agilent Technologies Inc. is engaged in the life sciences, diagnostics and applied chemical markets. The Company provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company has three business segments: the life sciences and applied markets business, the diagnostics and genomics business, and the Agilent CrossLab business. The Companys life sciences and applied markets business segment brings together the Companys analytical laboratory instrumentation and informatics. The Companys diagnostics and genomics business segment consists of three businesses: the Dako business, the genomics business and the nucleic acid solutions business. The Companys Agilent CrossLab business segment combines its analytical laboratory services and consumables business.